Thioredoxin Downregulation Enhances Sorafenib Effects in Hepatocarcinoma Cells

• Main Authors: María José López-Grueso (Author), Raúl González (Author), Jordi Muntané (Author), José Antonio Bárcena (Author), C. Alicia Padilla (Author)
• Formato: Livro
• Publicado em: MDPI AG, 2019-10-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Sorafenib is the first-line recommended therapy for patients with advanced hepatocarcinoma (HCC) in de-differentiation stage (presenting epithelial−mesenchymal transition, EMT). We studied the role of the thioredoxin system (Trx1/TrxR1) in the sensitivity or resistance of HCC cells to the treatment...